Article

Pharmacological Induction of FOXO3 Is a Potential Treatment for Sickle Cell Disease

2015-12-03

Abstract excerpt

Abstract Sickle cell disease (SCD) affects >100,000 Americans and millions more worldwide. Symptoms and sequelae of SCD can be ameliorated by increasing fetal hemoglobin (HbF, α2γ2) levels. Unfortunately, up to 50% of adult SCD patients treated with hydroxyurea, the only FDA-approved and widely used HbF inducer, do not have a clinically meaningful response to the drug. Additional oral HbF inducing agents, especial...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 205eb318-cee0-56a0-bbd1-fa1691b87cb7
DOI: 10.1182/blood.v126.23.282.282

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological Induction of FOXO3 Is a Potential Treatment for Sickle Cell DiseaseDOI 10.1182/blood.v126.23.282.282Read

Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cellsSemantic proximity Read

Modeling Genetic Diversity in Sickle Cell Disease Reveals Heterogeneous Responses to HbF-Inducing TherapiesSemantic proximity Read

Recent Advances in the Treatment of Sickle Cell DiseaseSemantic proximity Read

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Semantic proximity Read

Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.Semantic proximity Read

Fetal haemoglobin induction in sickle cell diseaseSemantic proximity Read

The future of sickle cell disease therapeutics rests in genomicsSemantic proximity Read

A replication study of novel fetal hemoglobin-associated genetic variants in sickle cell disease-only cohorts.Semantic proximity Read

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Semantic proximity Read

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell DiseaseSemantic proximity Read

βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid CellsSemantic proximity Read

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 <sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read